The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer

被引：14
|
作者：
Grinshpun, Albert [1 ,2 ,3 ]
Tolaney, Sara M. M. [1 ,2 ,3 ]
Burstein, Harold J. J.
Jeselsohn, Rinath [1 ,2 ,3 ]
Mayer, Erica L. L. [1 ,2 ,3 ]
机构：
[1] Dana Farber Canc Inst, Med Oncol, Boston, MA 02215 USA
[2] Dana Farber Brigham Canc Ctr, Breast Oncol Program, Boston, MA 02215 USA
[3] Harvard Med Sch, Boston, MA 02115 USA
来源：
NPJ BREAST CANCER | 2023年 / 9卷 / 01期
关键词：
RIBOCICLIB PLUS FULVESTRANT; MONALEESA-3; TRIAL; ABEMACICLIB PLUS; PATIENTS PTS; SURVIVAL; PALBOCICLIB; LETROZOLE; THERAPY; INTERIM; WOMEN;
D O I：
10.1038/s41523-023-00520-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The combination of an endocrine agent with a CDK4/6 inhibitor is the standard of care in the first-line setting for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Randomized trials have demonstrated similar and significant improvements in progression-free survival using the three available CDK4/6 inhibitors and led to regulatory approval. However, mature overall survival data now suggest potential differences among the various agents, suggesting an evolution in selection preferences.
引用
下载
收藏
页数：4
相关论文
共 50 条
  • [21] Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines
    Matutino, A.
    Joy, A. A.
    Brezden-Masley, C.
    Chia, S.
    Verma, S.
    CURRENT ONCOLOGY, 2018, 25 : S131 - S141
  • [22] Dissecting the biological activity of different CDK4/6 inhibitors (CDK4/6i) in hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
    Lorman-Carbo, Natalia
    Martinez-Saez, Olga
    Fernandez-Martinez, Aranzazu
    Galvan, Patricia
    Chic, Nuria
    Adamo, Barbara
    Vidal, Maria
    Munoz, Montserrat
    Perou, Charles M.
    Gavila, Joaquin
    Pascual, Tomas
    Prat, Aleix
    Braso-Maristany, Fara
    CANCER RESEARCH, 2023, 83 (05)
  • [23] Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative breast cancer in Japan
    Futamura, Manabu
    Nakayama, Takahiro
    Yoshinami, Tersuhiro
    Oshiro, Chiya
    Ishihara, Mikiya
    Morita, Midori
    Watanabe, Akira
    Taniguchi, Azusa
    Tsukabe, Masami
    Shimoda, Masafumi
    Mitta, Kanae
    Chihara, Yoko
    Yasojima, Hiroyuki
    Ouchi, Yoshimi
    Tokumaru, Yoshihisa
    Ishihara, Takuma
    Masuda, Norikazu
    CANCER RESEARCH, 2023, 83 (05)
  • [24] Preferences for the sequencing of first-line systemic treatments in metastatic hormone receptor-positive, HER2-negative breast cancer
    Al Mahmasani, Layal
    Amhaz, Ghid
    Abou Zeidane, Reine
    Chamseddine, Nathalie
    Hatab, Taha
    Sabbagh, Saad
    Charafeddine, Maya
    Assi, Hazem I.
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [25] Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Jeong, Hyehyun
    Jeong, Jae Ho
    Kim, Jeong Eun
    Ahn, Jin-Hee
    Jung, Kyung Hae
    Kim, Sung-Bae
    CANCER RESEARCH AND TREATMENT, 2022, 54 (02): : 469 - 477
  • [26] Disparities in receipt of CDK4/6 inhibitors with endocrine therapy as therapy for hormone receptor-positive, HER2-negative metastatic breast cancer in the real-world setting
    Kimmick, G.
    Pilehvari, A.
    You, W.
    Bonilla, G.
    Anderson, R.
    ANNALS OF ONCOLOGY, 2023, 34 : S373 - S373
  • [27] Overall survival analysis of first line CDK4/6 inhibitors in a large real-world cohort of patients with hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer.
    Ferraro, Emanuela
    Moiso, Enrico
    Safonov, Anton
    Cabel, Luc
    Loudon, Laura
    Dang, Chau T.
    Shen, Sherry
    Jhaveri, Komal L.
    Robson, Mark E.
    Chandarlapaty, Sarat
    Razavi, Pedram
    Modi, Shanu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] Evolving treatment patterns in hormone receptor-positive, HER2-negative metastatic breast cancer
    Lankford, M. L.
    Britton, S. L.
    Buettner, A. D.
    Scharf, M.
    Tiscione, B.
    Willey, J. P.
    Mahtani, R. L.
    CANCER RESEARCH, 2019, 79 (04)
  • [29] CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials
    Carlo Messina
    Carlo Cattrini
    Giulia Buzzatti
    Luigi Cerbone
    Elisa Zanardi
    Marco Messina
    Francesco Boccardo
    Breast Cancer Research and Treatment, 2018, 172 : 9 - 21
  • [30] CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis
    Agostinetto, E.
    Vian, L.
    Caparica, R.
    Bruzzone, M.
    Ceppi, M.
    Lambertini, M.
    Ponde, N.
    de Azambuja, E.
    ESMO OPEN, 2021, 6 (02)
12345